Cell and Gene Roundup: CAR T Breaks New Ground - Summary - MDSpire
Feature

Cell and Gene Roundup: CAR T Breaks New Ground

A campus-built therapy enters clinical trials as researchers refine gene editing and uncover new ways to control gene expression

  • April 15, 2026

  • 6 min

Share

The University of Colorado Anschutz has received FDA approval for a groundbreaking CAR T-cell therapy targeting CD64 in adults with relapsed or refractory acute myeloid leukemia (AML). This pioneering initiative aims to assess the therapy's safety and optimal dosage through a Phase 1 trial set to begin this summer. The program, utilizing campus-built resources, reflects the growing ambition in academic centers to streamline the process of moving cellular therapies from research to patient application, ultimately aiming to improve outcomes for patients with limited treatment options.

Original Source(s)

Cell and Gene Roundup: CAR T Breaks New Ground

  • April 15, 2026

Related Content

From Spectra to Structure: An Interview with Novogaia’s Tess Bevers

Novogaia’s transformer-based model converts untargeted mass spectra into structural predictions for early-stage drug discovery

Mass Spec Roundup: From Masterpieces to Microplastics

Advances in imaging, AI, and single-cell analysis reveal hidden chemistry in art, biology, and the environment

  • April 15, 2026

  • 6 min
Cancer Mutation Detection with Digital PCR

Evaluating rapid assays for the detection of somatic mutations in tissue and liquid biopsies

  • April 15, 2026

  • 9 min